News >

TAS-102 Expands Arsenal in Gastric Cancer, But Long Road Ahead for Research

Brandon Scalea
Published: Friday, May 24, 2019

Mark M. Zalupski, MD

Mark M. Zalupski, MD

Although the recently FDA-approved agent TAS-102 (trifluridine/tipiracil; Lonsurf) has shown modest activity in patients with advanced gastric cancer, this patient population as a whole still represents a significant unmet need, said Mark M. Zalupski, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication